Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation

BACKGROUND: When anti-VEGF (vascular endothelial growth factor) antibody bevacizumab is applied in neoadjuvant treatment of colorectal cancer patients with liver metastasis, 5–6 weeks between last bevacizumab dose and liver resection are currently recommended to avoid complications in wound and live...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Starlinger, P, Alidzanovic, L, Schauer, D, Maier, T, Nemeth, C, Perisanidis, B, Tamandl, D, Gruenberger, B, Gruenberger, T, Brostjan, C
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2012
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3464762/
https://ncbi.nlm.nih.gov/pubmed/22850548
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.342
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados